When it comes to orphan drugs, particularly gene therapy, the pricing problem stems from visibility rather than dollars.
Read More
When it comes to orphan drugs, particularly gene therapy, the pricing problem stems from visibility rather than dollars.
Patti Engel talks about the importance of having experience in the rare disease space.
Too often discussions about the price of orphan drugs focus on the most basic unit of measure: a therapy exchanged for currency.
RARE COLLECTIVE® is a trademark of Rare Collective, LLC. 